# First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b

> **NCT06517485** · PHASE1 · COMPLETED · sponsor: **Mersana Therapeutics** · enrollment: 142 (actual)

## Conditions studied

- Platinum Resistant Ovarian Cancer
- Non-Small Cell Adenocarcinoma

## Interventions

- **DRUG:** upifitamab rilsodotin

## Key facts

- **NCT ID:** NCT06517485
- **Lead sponsor:** Mersana Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-30
- **Primary completion:** 2022-05-31
- **Final completion:** 2022-08-03
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2024-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06517485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06517485, "First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06517485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*